Andra AP-fonden’s 10x Genomics TXG Stock Holding History

Andra AP-fonden’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,800	Closed	-$2.01M	–	610
2021 Q3	$2.01M	Sell	13,800 -7,600	-36%	-$1.3M	0.04%	551
2021 Q2	$4.19M	Buy	21,400 +6,800	+47%	+$1.23M	0.09%	482
2021 Q1	$2.64M	Buy	14,600 +10,600	+265%	+$1.83M	0.06%	525
2020 Q4	$566K	Buy	+4,000	New	+$580K	0.01%	588

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Andra AP-fonden's TXG Position: Q4 2021 in Review

Andra AP-fonden sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 13,800 shares — an estimated $2.01M sold.

Andra AP-fonden first reported a position in TXG in Q4 2020 and held it in 4 quarters. The position peaked at $4.19M in Q2 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Andra AP-fonden reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
Andra AP-fonden sold 13,800 10x Genomics shares in Q4 2021, an estimated $2.01M.
Andra AP-fonden first reported a position in 10x Genomics in Q4 2020 and held it in 4 quarters.
Andra AP-fonden's 10x Genomics position peaked at $4.19M in Q2 2021.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Andra AP-fonden's 13F filing for Q4 2021, filed 15 Feb 2022.